Recently, three large randomized trials have shown that sodium-glucose transport protein 2 (SGLT2) inhibitors, used for the treatment of DM, significantly reduce the risk for HF hospitalization [21,22,23]. This evidence concerns the gene SLC5A2 and hydrops fetalis.